关键信息
-
基因名
hfb1
- 应用
-
别名
Hydrophobin I Short name:HFBI
-
种属
Hypocrea jecorina
-
表达系统
E. coli
-
标签
N- His-SUMO
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P52754
-
表达区间
23-97aa
-
分子量
23.5 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
HFB1, or Hypoxia-Inducible Factor-1, is a critical regulator of cellular responses to hypoxia (low oxygen levels) and plays a vital role in various physiological and pathological processes, including tumor growth, angiogenesis, and inflammation. The study of recombinant HFB1 protein has gained significant attention in the field of biomedical research due to its potential applications in cancer therapy and regenerative medicine. By understanding the molecular mechanisms underlying HFB1's role in gene expression regulation under hypoxic conditions, researchers aim to uncover novel therapeutic strategies that can enhance oxygen delivery to tissues or inhibit tumor progression. The production of recombinant HFB1 protein allows for detailed biochemical analyses and functional assays, enabling investigators to dissect its interactions with other cellular signaling pathways. Moreover, the recombinant protein can be utilized in drug screening and development, as well as in the design of HFB1-based therapies that could improve outcomes for patients with hypoxia-related diseases. As such, the ongoing research efforts surrounding HFB1 and its recombinant form hold the promise of advancing our understanding of cellular oxygen sensing and developing innovative clinical applications.
